IBXX.F Stock Overview
Provides medical imaging technologies using magnetic resonance.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Imagion Biosystems Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.26 |
| 52 Week High | AU$1.87 |
| 52 Week Low | AU$0.18 |
| Beta | 1.89 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -95.73% |
| 5 Year Change | n/a |
| Change since IPO | -89.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBXX.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.7% |
| 1Y | n/a | 1.7% | 26.3% |
Return vs Industry: Insufficient data to determine how IBXX.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how IBXX.F performed against the US Market.
Price Volatility
| IBXX.F volatility | |
|---|---|
| IBXX.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IBXX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IBXX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | imagionbiosystems.com |
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer.
Imagion Biosystems Limited Fundamentals Summary
| IBXX.F fundamental statistics | |
|---|---|
| Market cap | US$1.59m |
| Earnings (TTM) | -US$8.60m |
| Revenue (TTM) | US$3.41m |
0.5x
P/S Ratio-0.2x
P/E RatioIs IBXX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBXX.F income statement (TTM) | |
|---|---|
| Revenue | AU$5.18m |
| Cost of Revenue | AU$5.25m |
| Gross Profit | -AU$71.27k |
| Other Expenses | AU$12.99m |
| Earnings | -AU$13.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -1.38% |
| Net Profit Margin | -252.26% |
| Debt/Equity Ratio | -75.8% |
How did IBXX.F perform over the long term?
See historical performance and comparison